These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 39049036)

  • 1. Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response.
    Sadeghirad H; Monkman J; Tan CW; Liu N; Yunis J; Donovan ML; Moradi A; Jhaveri N; Perry C; Adams MN; O'Byrne K; Warkiani ME; Ladwa R; Hughes BGM; Kulasinghe A
    J Transl Med; 2024 Jul; 22(1):677. PubMed ID: 39049036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
    Liu Z; Meng X; Tang X; Zou W; He Y
    Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-A
    Zhang D; Jiang D; Jiang L; Ma J; Wang X; Xu X; Chen Z; Jiang M; Ye W; Wang J; Meng W; Qiu W; Hou Y; Huang J; Jiao Y; Liu Y; Liu Z
    Br J Cancer; 2024 Jul; 131(1):184-195. PubMed ID: 38762674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV
    Li H; Zhu SW; Zhou JJ; Chen DR; Liu J; Wu ZZ; Wang WY; Zhang MJ; Sun ZJ
    J Dent Res; 2023 Jun; 102(6):678-688. PubMed ID: 36883630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
    Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
    Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of tertiary lymphoid structures on tumor prognosis and the immune microenvironment in non-small cell lung cancer.
    Weng Y; Yuan J; Cui X; Wang J; Chen H; Xu L; Chen X; Peng M; Song Q
    Sci Rep; 2024 Jul; 14(1):16246. PubMed ID: 39009684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma.
    Liang H; Zhang Z; Guan Z; Zheng S; Lou J; Liu W; Cai Q; Si Y
    Front Immunol; 2023; 14():1096220. PubMed ID: 36776859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tertiary lymphoid structures in head and neck squamous cell carcinoma improve prognosis by recruiting CD8
    Wang M; Zhai R; Wang M; Zhu W; Zhang J; Yu M; Zhang W; Ye J; Liu L
    Mol Oncol; 2023 Aug; 17(8):1514-1530. PubMed ID: 36825382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
    Gavrielatou N; Fortis E; Spathis A; Anastasiou M; Economopoulou P; Foukas GRP; Lelegiannis IM; Rusakiewicz S; Vathiotis I; Aung TN; Tissot S; Kastrinou A; Kotsantis I; Vagia EM; Panayiotides I; Rimm DL; Coukos G; Homicsko K; Foukas P; Psyrri A
    Ann Oncol; 2024 Apr; 35(4):340-350. PubMed ID: 38159908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
    Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
    BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma.
    Secrier M; McGrath L; Ng F; Gulati S; Raymond A; Nuttall BRB; Berthe J; Jones EV; Sidders BS; Galon J; Barrett JC; Angell HK
    Cancer Res Commun; 2023 Oct; 3(10):2133-2145. PubMed ID: 37819239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tertiary lymphoid structures associated with enhanced anti-tumor immunity and favorable prognosis in cervical squamous carcinoma.
    Xiong G; Shan J; Chong Q; Cui Y
    Aging (Albany NY); 2024 Apr; 16(8):6898-6920. PubMed ID: 38709170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
    Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
    BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tertiary lymphoid structures in the era of cancer immunotherapy.
    Sautès-Fridman C; Petitprez F; Calderaro J; Fridman WH
    Nat Rev Cancer; 2019 Jun; 19(6):307-325. PubMed ID: 31092904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.
    Lim SM; Kang SS; Kim DK; Lee SH; Synn CB; Baek S; Yang SM; Han YJ; Kim MH; Han H; Na K; Kim YT; Yun MR; Kim JH; Byeon Y; Kim YS; Lee JB; Hong MH; Curtin JC; Patel B; Bergiers I; Pyo KH; Cho BC
    Cancer Res Commun; 2024 Jul; 4(7):1748-1764. PubMed ID: 38916448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma.
    Gong W; Zhang S; Tian X; Chen W; He Y; Chen L; Ding T; Ren P; Shi L; Wu Q; Sun Y; Chen L; Guo H
    Hepatol Int; 2024 Aug; 18(4):1310-1325. PubMed ID: 38767772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
    Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C
    J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
    Masuda T; Tanaka N; Takamatsu K; Hakozaki K; Takahashi R; Anno T; Kufukihara R; Shojo K; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.